ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
3.890
+0.080 (2.10%)
At close: Nov 13, 2026, 4:00 PM EST
3.850
-0.040 (-1.03%)
After-hours: Nov 13, 2026, 7:30 PM EST
ARS Pharmaceuticals Employees
As of September 30, 2026, ARS Pharmaceuticals had 206 total employees, including 203 full-time and 3 part-time employees. The number of employees increased by 39 or 23.35% compared to the same quarter last year. That makes ARS Pharmaceuticals the 26,609th largest employer in the world and 3,349th in the United States.
Employees
206
Change (1Y)
39
Growth (1Y)
23.35%
Revenue / Employee
$592,893
Profits / Employee
-$970,233
Market Cap
391.06M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2026 | 206 | 39 | 23.35% | 203 | 3 |
| Jun 30, 2026 | 200 | 33 | 19.76% | 195 | 5 |
| Mar 31, 2026 | 159 | -1 | -0.63% | 154 | 5 |
| Dec 31, 2025 | 163 | 3 | 1.88% | 158 | 5 |
| Sep 30, 2025 | 167 | 16 | 10.60% | 162 | 5 |
| Jun 30, 2025 | 167 | 139 | 496.43% | 162 | 5 |
| Dec 31, 2024 | 160 | 134 | 515.38% | 155 | 5 |
| Sep 30, 2024 | 151 | 124 | 459.26% | 146 | 5 |
| Jun 30, 2024 | 28 | -6 | -17.65% | 23 | 5 |
| Mar 31, 2024 | 26 | -5 | -16.13% | 24 | 2 |
| Dec 31, 2023 | 26 | 6 | 30.00% | 24 | 2 |
| Sep 30, 2023 | 27 | 16 | 145.45% | 24 | 3 |
| Jun 30, 2023 | 34 | 23 | 209.09% | 29 | 5 |
| Mar 31, 2023 | 31 | 22 | 244.44% | 27 | 4 |
| Dec 31, 2022 | 20 | 11 | 122.22% | 17 | 3 |
| Jun 30, 2022 | 11 | - | - | 9 | 2 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CorMedix | 191 |
| Lyell Immunopharma | 161 |
| MapLight Therapeutics | 133 |
| C4 Therapeutics | 104 |
| Alector | 103 |
| TRex Bio | 60 |
| Contineum Therapeutics | 51 |
| Fennec Pharmaceuticals | 35 |
SPRY News
- 9 days ago - ARS Pharmaceuticals price target lowered to $20 from $30 at Cantor Fitzgerald - TheFly
- 9 days ago - ARS Pharmaceuticals downgraded to Outperform from Strong Buy at Raymond James - TheFly
- 9 days ago - ARS Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 9 days ago - ARS Pharmaceuticals Earnings release: Q3 2026 - Filings
- 9 days ago - ARS Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 9 days ago - ARS Pharmaceuticals reports Q3 EPS (36c), consensus (33c) - TheFly
- 17 days ago - ARS Pharma to Report Third Quarter 2026 Financial Results - GlobeNewsWire
- 7 weeks ago - Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026 - GlobeNewsWire